Search
Search Results
-
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Alzheimer’s disease (AD) is a neurodegenerative condition that causes cognitive decline, memory loss, and reduced personal autonomy. The pathology of...
-
Aducanumab: an uprising hope with vague horizons
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Amyloid-beta (Aβ) deposition, is one of the processes involved in the...
-
Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
BackgroundAlzheimer's Disease (AD), the most common type of dementia, is a chronic, progressive, and neurodegenerative brain discomfort that causes...
-
Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval
Aducanumab is the first FDA-approved amyloid-lowering immunotherapy for Alzheimer’s disease. There is little real-world data to guide management of...
-
Aducanumab: Appropriate Use Recommendations Update
Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer’s disease or mild...
-
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab
ObjectivesEfficacy and safety results from the EMERGE (NCT02484547) and ENGAGE (NCT02477800) phase 3 studies of aducanumab in early Alzheimer’s...
-
Alzheimer disease neuropathology in a patient previously treated with aducanumab
Amyloid beta (Aβ) plaque is a defining pathologic feature of Alzheimer disease (AD). Aducanumab, a monoclonal IgG1 that selectively binds aggregated...
-
Aducanumab: First Approval
Aducanumab (aducanumab-avwa; Aduhelm™) is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and...
-
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease
BackgroundAlzheimer’s disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role...
-
Aducanumab: Appropriate Use Recommendations
Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer’s disease (AD). Clinicians require guidance on the...
-
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
IntroductionAlzheimer’s disease (AD) is a chronic and progressive neurodegenerative disease that places a substantial burden on patients and...
-
Can we learn lessons from the FDA’s approval of aducanumab?
On 7 June 2021, aducanumab was granted accelerated approval for the treatment of Alzheimer disease (AD) by the FDA on the basis of amyloid-lowering...
-
Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab
The US Food and Drug Administration’s decisions about drug approval—though guided by science, as well as relevant statutes, regulations, and guidance...
-
